← All trials
NCT05010200
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2021
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2031
- First posted
- Aug 18, 2021
- Last posted
- Aug 18, 2021
- Enrollment
- 27
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Icahn School of Medicine at Mount SinaiLead sponsor
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiSponsor investigator
- Icahn School of Medicine at Mount SinaiStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.